In patients with type 2 diabetes and CV disease, empagliflozin reduces CV and all-cause mortality

Mark H. Ebell

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'In patients with type 2 diabetes and CV disease, empagliflozin reduces CV and all-cause mortality'. Together they form a unique fingerprint.